Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$25.14
$0.49(1.79%)
At close: 4:00 PM EDT
$25.14
$0.49(1.79%)
Day’s Range― - ―
52-Week Range$15.93 - $31.77
Previous Close$28.11
Volume1.20M
Average Volume (3M)1.60M
Market Cap
$3.00B
Enterprise Value$3.44K
Total Cash (Recent Filing)$238.55M
Total Debt (Recent Filing)$114.14M
Price to Earnings (P/E)107.2
Beta0.71
Next Earnings
Oct 29, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding125,691,960
10 Day Avg. Volume1,693,511
30 Day Avg. Volume1,600,781
Financial Highlights & Ratios
PEG Ratio2.52
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.57Price Target Upside45.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.22
Revenue Forecast (FY)$500.06M
Bulls Say, Bears Say
Bulls Say
ZORYVE Commercial GrowthRapid prescription and revenue growth indicates expanding adoption of ZORYVE across dermatology indications. A larger commercial base can support recurring product sales and improve operating leverage as the franchise scales.
Profitability And Cash Flow InflectionThe shift from losses and cash burn to positive earnings and free cash flow strengthens internal funding capacity. Sustained cash conversion would reduce reliance on external capital while supporting commercial and pipeline investment.
Franchise Expansion And IP ProtectionAdditional age groups, indications, and patent protection expand the addressable market and support longer commercial durability. Regulatory progress and exclusivity may help preserve differentiation as the franchise broadens.
Bears Say
Gross-to-net PressureLarge deductions for rebates, access programs, and other discounts limit the conversion of prescription growth into net revenue. Persistent gross-to-net pressure could constrain gross-margin expansion and reduce the benefit of scale.
Commercial Cost IntensityBuilding the salesforce and patient-access infrastructure should support future demand, but it raises the fixed cost base. If revenue growth slows, elevated commercial spending could compress operating margins and delay durable profitability.
Pipeline And Leadership Execution RiskPipeline expansion depends on uncertain clinical outcomes, while a commercial leadership transition adds execution risk during rapid growth. Delayed or negative readouts, or weaker continuity, could limit diversification beyond ZORYVE.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $15.93 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $3.00B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Aug 05, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.055 by $0.055.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is 0.18.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 125,691,960 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of $0.11 in its last earnings report, beating expectations of $0.055. Following the earnings report the stock price went down -2.472%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.57 (45.47% Upside)
$36.57 (45.47% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 75%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated robust commercial momentum and multiple strategic wins — sizable revenue growth (+59% YoY), a return to quarterly profitability, raised full-year guidance, recent pediatric approval and an accepted sNDA — while simultaneously investing heavily in commercial expansion, patient access initiatives, and a broad pipeline. Near-term challenges include elevated SG&A from the salesforce build, gross-to-net still in the 50s with only moderate near-term improvement, early-stage readout risk on several programs, and some uncertainty around telehealth conversion dynamics. On balance, positive operational and financial momentum outweigh the manageable risks.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$36.57
▲(45.47% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.51% Insiders
16.01% Mutual Funds
48.32% Other Institutional Investors
12.68% Public Companies and
Individual Investors